Anna E. Vilgelm

Anna E. Vilgelm's research focuses on cancer biology and immunotherapy, particularly in melanoma and breast cancer, investigating how tumor cells evade immune attack and how combination treatments (such as kinase inhibitors, cell-based vaccines, and NK/T-cell therapies) can overcome resistance to immune checkpoint therapies. The work spans preclinical mouse models, patient-derived tumor models, and imaging techniques to track immune cell responses in vivo. Prospective students would likely engage in laboratory-based cancer immunology research combining molecular biology, animal models, and translational therapeutic testing.

Publication output grew steadily from 2017 to 2021, spiked sharply in 2023 (largely due to supplementary materials from a few studies), then returned to a more moderate but still active pace through 2026.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026